07:00 , Aug 25, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Respiratory syncytial virus (RSV) Nucleolin In vitro and mouse studies suggest nucleolin inhibitors could help prevent...
07:00 , May 30, 2011 |  BioCentury  |  Finance

Europe's Iceberg 2011: A rising tide; demand to match

Europe's biotech industry is maturing, as a handful of public companies are transitioning from sizable cash burners to commercial enterprises, while the number of private clinical-stage companies has reached record levels. Indeed, BioCentury's 9th Annual European...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Company News

Antisoma cancer news

Antisoma said it will seek partners for its development programs after concluding an offer period soliciting a sale of the biotech. Antisoma said it concluded the offer period to take a longer-term approach to explore...
07:00 , Apr 4, 2011 |  BioCentury  |  Finance

Eleventh Hour Push

A last minute surge led by large cap stocks enabled biotech indices to post a strong performance for the first quarter. Prior to that, biotech had been relatively flat or down for most of the...
07:00 , Mar 14, 2011 |  BC Week In Review  |  Company News

Antisoma cancer news

Antisoma reduced headcount to about 10 as part of its previously announced restructuring to save cash. The cuts include CMO Gray Acton. The company plans to further reduce headcount next month. In January, Antisoma announced...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Company News

Antisoma cancer news

Antisoma will reduce headcount by about 40-50 to about 10 by March 31 as part of its previously announced restructuring to save cash. Antisoma announced plans to immediately restructure last month after discontinuing development of...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Clinical News

Amonafide L-malate: Development discontinued

Antisoma discontinued development of amonafide after data from the open-label, international Phase III ACCEDE trial in over 420 patients showed that 600 mg/m 2 IV amonafide for 5 days plus cytarabine missed the primary endpoint...
08:00 , Feb 7, 2011 |  BC Week In Review  |  Clinical News

AS1411: Phase IIb discontinued

Antisoma discontinued an open-label, international Phase IIb trial of AS1411 after early data from about 45 patients showed that the compound was unlikely to show a clear benefit. The company said it will focus on...
01:13 , Feb 1, 2011 |  BC Extra  |  Clinical News

Antisoma plunges after misses in AML

Antisoma plc (LSE:ASM) fell 4.03p (64%) to 2.22p on Monday after announcing that it discontinued development of acute myelogenous leukemia (AML) candidate amonafide ( AS1413). The decision came after data from the open-label, international Phase...
07:00 , Apr 5, 2010 |  BioCentury  |  Product Development

No Regrets for Antisoma

The vagaries of drug development are such that even carefully thought out clinical programs can fail. Thus Antisoma plc says it has no regrets about the way it and partner Novartis AG have run development...